Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trastuzumab-DOTA-GA is an antibody-radio conjugate (ARC) precursor consisting of the HER2-targeted monoclonal antibody trastuzumab conjugated to the chelating agent DOTA-GA (DOTAGA). Developed by Debiopharm and Oncodesign Services using Debiopharm's proprietary AbYlink™ regioselective conjugation technology, the payload is site-specifically attached to the Fc region of the antibody, preserving its antigen-binding affinity. The DOTA-GA chelator enables subsequent radiolabeling with various isotopes, such as Indium-111, Gallium-68, or Lutetium-177, for applications in molecular imaging (SPECT/PET) and targeted radionuclide therapy. It is currently in preclinical development for the detection and treatment of HER2-positive cancers, including gastric cancer.
| Indication | Highest phase | Status |
|---|---|---|
| gastric cancer and precursor lesions | Preclinical | Active |
Every indication, with countries and timelines, is in the full profile.
| Market | Status | Year |
|---|---|---|
| United States | Not approved | — |
| European Union | Not approved | — |
| China | Not approved | — |
| Japan | Not approved | — |
Approved indications and other markets are in the full profile.
Lead indication: gastric cancer and precursor lesions
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on trastuzumab-DOTA-GA.
Work on trastuzumab-DOTA-GA? Claim this page to correct or add information. Claim this page